Literature DB >> 25386467

Impact of amitryptiline on migraine disability assessment score.

Kuldeep Moras1, Hanock Nischal2.   

Abstract

AIM: Migraine headache is a common disorder, several drugs have been tried as a prophylaxis to reduce the attacks of headache. AIM of this study is to see the impact of amitriptyline on quality of life in migraneurs using Migraine Disability Assessment Score.
MATERIALS AND METHODS: In this study 300 patients of either gender who required prophylaxis for migraine without aura were selected. The patients were of the age group 18-60 years. The MIDAS questionnaire was administered to patients before starting treatment and again after 45 days prophylaxis. The improvement was noted. STATISTICAL ANALYSIS: It is a prospective study where the severity of symptoms and 'quality of life' in patients is assessed before and after treatment using mean, frequency, standard deviation and paired't' test.
RESULTS: A total of 300 patients were subjected to migraine prophylaxis with amiptriptyline. The study showed female preponderance. The mean MIDAS score before and after treatment with amitriptyline was 11.6 and 9.4 respectively. The student't' test showed p-value of <0.005 which was significant.
CONCLUSION: Migraine prophylaxis with amitriptyline for a period of 45 days decreased the severity of symptoms and also reduction in days of migraine attacks. However the long term effects on quality of life could not be assessed. The study needs to be conducted in a large scale to evaluate the consistency and accuracy of the test.

Entities:  

Keywords:  Amytriptyline; Midas

Year:  2014        PMID: 25386467      PMCID: PMC4225919          DOI: 10.7860/JCDR/2014/7546.4854

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  9 in total

1.  Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers.

Authors:  W F Stewart; R B Lipton; K B Kolodner; J Sawyer; C Lee; J N Liberman
Journal:  Pain       Date:  2000-10       Impact factor: 6.961

Review 2.  Prophylactic pharmacotherapy for migraine headaches.

Authors:  Thomas M Buchanan; Nabih M Ramadan
Journal:  Semin Neurol       Date:  2006-04       Impact factor: 3.420

Review 3.  Allergic rhinitis--history and presentation.

Authors:  Rose J Eapen; Charles S Ebert; Harold C Pillsbury
Journal:  Otolaryngol Clin North Am       Date:  2008-04       Impact factor: 3.346

4.  Migraine in the United States: epidemiology and patterns of health care use.

Authors:  R B Lipton; A I Scher; K Kolodner; J Liberman; T J Steiner; W F Stewart
Journal:  Neurology       Date:  2002-03-26       Impact factor: 9.910

Review 5.  Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability.

Authors:  W F Stewart; R B Lipton; A J Dowson; J Sawyer
Journal:  Neurology       Date:  2001       Impact factor: 9.910

6.  Does early migraine treatment shorten time to headache peak and reduce its severity?

Authors:  X Henry Hu; Daisy Ng-Mak; Roger Cady
Journal:  Headache       Date:  2007-11-13       Impact factor: 5.887

7.  Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs.

Authors:  David W Dodick; Fred Freitag; James Banks; Joel Saper; Jim Xiang; Marcia Rupnow; David Biondi; Steven J Greenberg; Joseph Hulihan
Journal:  Clin Ther       Date:  2009-03       Impact factor: 3.393

8.  Migraine prodromes separated from the aura: complete migraine.

Authors:  J N Blau
Journal:  Br Med J       Date:  1980-09-06

9.  A double-blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study.

Authors:  Ninan T Mathew; Sayyed Farhan A Jaffri
Journal:  Headache       Date:  2009 Nov-Dec       Impact factor: 5.887

  9 in total
  1 in total

1.  The challenge of managing headache disorders in a tertiary referral neurology clinic in Rwanda.

Authors:  Celestin Kaputu-Kalala-Malu; Timothy D Walker; Olga Ntumba-Tshitenge; Eric M Mafuta; Pierrot L Tugirimana; Jean P Misson
Journal:  Neurosciences (Riyadh)       Date:  2016-04       Impact factor: 0.906

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.